Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
about
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersAdvances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum DisorderExcitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum DisordersFragile X spectrum disordersThe efficacy of specific neuromodulators on human refractory chronic cough: a systematic review and meta-analysisFragile X syndrome: A review of clinical managementThe neurobiology of the Prader-Willi phenotype of fragile X syndromeFragile X mental retardation protein: A paradigm for translational control by RNA-binding proteinsDeletion of Fmr1 alters function and synaptic inputs in the auditory brainstem.GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Fmr1 Knockout Mouse Model of Fragile X Syndrome.Fragile X Syndrome: Prevalence, Treatment, and Prevention in ChinaIdentification of a male with fragile X syndrome through newborn screeningThe FMRP/GRK4 mRNA interaction uncovers a new mode of binding of the Fragile X mental retardation protein in cerebellumImbalance between Glutamate and GABA in Fmr1 Knockout Astrocytes Influences Neuronal Development.Serotonin dysregulation in Fragile X Syndrome: implications for treatment.Public Health Literature Review of Fragile X Syndrome.Neuron class-specific requirements for Fragile X Mental Retardation Protein in critical period development of calcium signaling in learning and memory circuitry.KCC2 expression supersedes NKCC1 in mature fiber cells in mouse and rabbit lenses.Protein synthesis levels are increased in a subset of individuals with Fragile X syndrome.
P2860
Q26748728-4255AC53-2B94-49D5-BAC9-1839F00F01C0Q26781265-08F19035-CA60-46F0-B0A3-C789728E64BCQ26796321-55A2E511-E8EC-48AB-973D-A786214D236FQ26824376-DC351EAB-7A1B-404F-9799-13655FF6883BQ28072181-B5AC9AC0-9EA5-4799-9924-904C976D67E1Q28076950-2E18BA14-1A77-4071-A52A-7849B1B585BAQ28078294-0D959F43-340C-4A2B-A393-1114B1E87C76Q28086823-5EE939F9-A253-478A-9535-2FDD2ECFDA68Q30418164-8DEB1B23-4195-42CF-B315-43815C3F2C41Q33573692-BC77C2B9-08C3-43D0-8E26-0AFC9CC17558Q33766106-8560CE92-9A41-49E5-8364-313272A4A105Q36322068-A7B822AB-F39C-48A7-9CEE-A2BE0F99CC4AQ36676669-8F15FF1E-BE84-4578-B330-1E94528B58CEQ37208978-8CC8D5A4-CE1B-405B-9071-EDD5D3965637Q38326506-7653B422-E90E-4E8B-BCAF-6E8CB1FE9D6FQ38641503-89576F24-D395-4785-987F-892710663F61Q38884036-AC8B770C-0FDB-4B77-A232-9CE38B4D055AQ43221195-84B35C8B-D4FE-45AB-B9A7-4D9047BBA716Q51733403-D7CAF4EB-CB5B-4C51-9B63-1896DE31F3E0
P2860
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@ast
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@en
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@nl
type
label
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@ast
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@en
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@nl
prefLabel
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@ast
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@en
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@nl
P2093
P2860
P356
P1476
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
@en
P2093
Emma B Hare
Randi J Hagerman
Reymundo Lozano
P2860
P304
P356
10.2147/NDT.S42919
P407
P577
2014-09-16T00:00:00Z